Aspirin, which is commonly repurposed for several different uses, has been shown to reduce the risk of colorectal cancer. However, a new study at the University of Minnesota has elucidated just how the drug is able to do so. A tissue growth factor known as EGFR is often overexpressed in patients with colorectal cancer, and aspirin works to decrease the abundance of this compound. Now that the molecular mechanism is known, further clinical studies are being performed to determine whether or not aspirin could be used prophylactically to decrease the risk of other cancers.


Science Daily
See article in EBioMedicine here